246 related articles for article (PubMed ID: 35164657)
1. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro.
Ji J; Feng M; Huang Y; Niu X
Bioengineered; 2022 Mar; 13(3):5091-5102. PubMed ID: 35164657
[TBL] [Abstract][Full Text] [Related]
2. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways.
Luo Y; Yang P; Li Z; Luo Y; Shen J; Li R; Zheng H; Liang Y; Xia N
Drug Des Devel Ther; 2019; 13():4065-4074. PubMed ID: 31819375
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.
Jiang JX; Chen X; Fukada H; Serizawa N; Devaraj S; Török NJ
Hepatology; 2013 Oct; 58(4):1339-48. PubMed ID: 23703665
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice.
Lin CP; Huang PH; Chen CY; Wu MY; Chen JS; Chen JW; Lin SJ
Sci Rep; 2021 Sep; 11(1):17851. PubMed ID: 34497344
[TBL] [Abstract][Full Text] [Related]
6. Dietary glycotoxins exacerbate progression of experimental fatty liver disease.
Leung C; Herath CB; Jia Z; Goodwin M; Mak KY; Watt MJ; Forbes JM; Angus PW
J Hepatol; 2014 Apr; 60(4):832-8. PubMed ID: 24316518
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice.
Li P; Tang Z; Wang L; Feng B
Mol Med Rep; 2017 Sep; 16(3):3421-3426. PubMed ID: 28713911
[TBL] [Abstract][Full Text] [Related]
8. The NOX1 isoform of NADPH oxidase is involved in dysfunction of liver sinusoids in nonalcoholic fatty liver disease.
Matsumoto M; Zhang J; Zhang X; Liu J; Jiang JX; Yamaguchi K; Taruno A; Katsuyama M; Iwata K; Ibi M; Cui W; Matsuno K; Marunaka Y; Itoh Y; Torok NJ; Yabe-Nishimura C
Free Radic Biol Med; 2018 Feb; 115():412-420. PubMed ID: 29274380
[TBL] [Abstract][Full Text] [Related]
9. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice.
Paik YH; Iwaisako K; Seki E; Inokuchi S; Schnabl B; Osterreicher CH; Kisseleva T; Brenner DA
Hepatology; 2011 May; 53(5):1730-41. PubMed ID: 21384410
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide improved the cognitive function of diabetic mice via the receptor of advanced glycation end products down-regulation.
Zhang H; Chu Y; Zheng H; Wang J; Song B; Sun Y
Aging (Albany NY); 2020 Nov; 13(1):525-536. PubMed ID: 33298623
[TBL] [Abstract][Full Text] [Related]
11. [Liraglutide protects against nonalcoholic fatty liver disease in ApoE knockout mice with high-fat diet and silenced Acrp30 by increasing AMPK].
Zhao XY; Zhang LL; Suolang QZ; Yang GY; Li L; Li SB; Chen WW
Zhonghua Gan Zang Bing Za Zhi; 2014 Nov; 22(11):849-53. PubMed ID: 25531383
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 4 plays a key role in advanced glycation end products-induced M1 macrophage polarization.
Liu Z; Ma Y; Cui Q; Xu J; Tang Z; Wang Y; He C; Wang X
Biochem Biophys Res Commun; 2020 Oct; 531(4):602-608. PubMed ID: 32814631
[TBL] [Abstract][Full Text] [Related]
13. Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease.
Pereira ENGDS; Silvares RR; Flores EEI; Rodrigues KL; Ramos IP; da Silva IJ; Machado MP; Miranda RA; Pazos-Moura CC; Gonçalves-de-Albuquerque CF; Faria-Neto HCC; Tibiriça E; Daliry A
PLoS One; 2017; 12(6):e0179654. PubMed ID: 28628674
[TBL] [Abstract][Full Text] [Related]
14. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer.
Petriv N; Neubert L; Vatashchuk M; Timrott K; Suo H; Hochnadel I; Huber R; Petzold C; Hrushchenko A; Yatsenko AS; Shcherbata HR; Wedemeyer H; Lichtinghagen R; Falfushynska H; Lushchak V; Manns MP; Bantel H; Semchyshyn H; Yevsa T
Oncoimmunology; 2021 Feb; 10(1):1874159. PubMed ID: 33628620
[TBL] [Abstract][Full Text] [Related]
15. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
Li Z; Feng PP; Zhao ZB; Zhu W; Gong JP; Du HM
Biochem Biophys Res Commun; 2019 Feb; 510(1):20-26. PubMed ID: 30683312
[TBL] [Abstract][Full Text] [Related]
16. JNK and ATF4 as two important platforms for tumor necrosis factor-α-stimulated shedding of receptor for advanced glycation end products.
Miyoshi A; Koyama S; Sasagawa-Monden M; Kadoya M; Konishi K; Shoji T; Inaba M; Yamamoto Y; Koyama H
FASEB J; 2019 Mar; 33(3):3575-3589. PubMed ID: 30452882
[TBL] [Abstract][Full Text] [Related]
17. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
18. Idebenone reduces sepsis-induced oxidative stress and apoptosis in hepatocytes via RAGE/p38 signaling.
Gou T; Jin X; Xia J
Ann Transl Med; 2022 Dec; 10(24):1363. PubMed ID: 36660726
[TBL] [Abstract][Full Text] [Related]
19. [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].
Gao H; Xu L; Li D; Guang L; Deng W
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1661-4. PubMed ID: 24273273
[TBL] [Abstract][Full Text] [Related]
20. A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.
Trasino SE; Tang XH; Jessurun J; Gudas LJ
J Mol Med (Berl); 2016 Oct; 94(10):1143-1151. PubMed ID: 27271256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
